tradingkey.logotradingkey.logo
Discount

PR Newswire

5363 Articles

Founded in 1954 by Herbert Muschel and acquired by Cision in 2015, PR Newswire is the industry’s leading press release distribution partner with a global reach of over 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages.

DiDi Shareholders Overwhelmingly Back Hong Kong Relisting; Want Independent Director, Open Earnings Calls, and First Shareholder Meeting in Four Years, Survey Finds

A Heng Ren Partners survey this month finds at least 99.3% support on five key shareholder issues to boost shareholder value; shareholders want DiDi's board and management to respond with concrete action BOSTON, Oct. 26, 2026 /PRNewswire/ -- Heng Ren Partners LLC, an active asset manager whose ...
Sun, Oct 25

World Young Scientist Summit 2026 Opens in Wenzhou, Zhejiang

WENZHOU, China, Oct. 25, 2026 /PRNewswire/ -- A news report from China Daily: On October 24, the World Young Scientist Summit 2026 opened in Wenzhou, Zhejiang. The event is hosted by the China Association for Science and Technology (CAST), the Zhejiang Provincial People's Government, and the Wo...
Sun, Oct 25

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89; one-sided P = 0.0021). The 2-year OS rate was 54.1% vs 37.2%, an improvement of 16.9%; with a median follow-up of 32.3...
Sun, Oct 25

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine

PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95%CI 0.36-0.65; P<0.0001 ), and medianPFS was 15.0 months (95% CI 9.9-NE) and 5.7 months (95% CI 5.5-7.4) in the two groups, respectively. Responses were more durable: me...
Sun, Oct 25

Ping An Highlights Green Development Initiatives at International Communication Seminar in Shenzhen Ahead of APEC 2026

HONG KONG and SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- The Seminar on International Communication of Chinese and Foreign Enterprises' Green Development and Global Contributions was held at the Ping An Finance Center inShenzhen on October 23. Hosted by the China Public Relations Association and co...
Sun, Oct 25

2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic,...
Sun, Oct 25

2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

SAN FRANCISCO andSUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, ...
Sun, Oct 25

ST Engineering iDirect and MBSat Partner to Build Next-Generation Sovereign Connectivity Services Across Oman and the Middle East

Intuition ground system selected to support MBSat's planned 2027 service launch, enabling accelerated deployment, dynamic resource management and scalable service growth HERNDON, Va., Oct. 25, 2026 /PRNewswire/ -- ST Engineering iDirect today announced a strategic partnership with Mohammed Al B...
Sun, Oct 25

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 25, 2026 /PRNewswire/ -- At the 2026ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients with advanced NUT carcinoma (NC). In ...
Sun, Oct 25

World Young Scientist Summit 2026 Opens in Wenzhou, Zhejiang

WENZHOU, China, Oct. 24, 2026 /PRNewswire/ -- This is a report by China Daily: On October 24, the World Young Scientist Summit 2026 opened in Wenzhou, Zhejiang. The event is hosted by the China Association for Science and Technology (CAST), the Zhejiang Provincial People's Government, and the W...
Sat, Oct 24

The Ultimate Send-off to Summer: CSTS Debuts Global Entertainment IP PremierX at New York's Pier 17, Ushering in a New Era of Live Entertainment

NEW YORK, Oct. 24, 2026 /PRNewswire/ -- CSTS Enterprises ('CSTS'), a New York-based sports, entertainment, integrated media and travel technology group, today announced the official launch of PremierXTM, its flagship live entertainment brand, with a landmark Halloween Weekend event "AFTE...
Sat, Oct 24

Technology Drives the Future of Travel: JETOUR Continues to Expand Its "Travel+" Ecosystem

WUHU, China, Oct. 24, 2026 /PRNewswire/ -- Expectations for travel are evolving: vehicles are no longer simply a means of reaching a destination, but travel companions that bring people closer to nature, serving as a "mobile third space." Technology Drives the Future of Travel: JETOUR Co...
Sat, Oct 24

Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026

BEIJING, Oct. 24, 2026 /PRNewswire/ -- Likang Life Sciences ("Likang"), a biotechnology company advancing AI-enabled personalized cancer immunotherapies, sponsored and exhibitedat the Abu Dhabi Future Health Summit 2026, held from 20 to 22 October at ADNEC Centre Abu Dhabi. The summit marked...
Sat, Oct 24

Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO

CHENGDU, China, Oct. 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, updated results from the Phase II MK-2870-002/S...
Sat, Oct 24

2026 China Marine Economy Expo Kicks Off: Embarking Together on a Journey Toward Digital and Smart Ocean

SHENZHEN, China, Oct. 24, 2026 /PRNewswire/ -- On October 22,Shenzhen World Exhibition & Convention Center was illuminated in a deep ocean blue as the 2026 China Marine Economy Expo—themed "Digital and Smart Ocean: Co-creating a Sustainable Future"—officially opened. Spanning an exhibiti...
Sat, Oct 24

ASTRI Showcases Pioneering Technologies at InnoCarnival 2026

Driving Technology Adoption, Shaping a Vision for the Future HONG KONG, Oct. 24, 2026 /PRNewswire/ -- The Hong Kong Applied Science and Technology Research Institute (ASTRI) is proud to present a range of cutting-edge technologies and practical solutions at this year's InnoCarnival, spanning co...
Sat, Oct 24

HKAGE Showcases Gifted Students' Learning Journeys at InnoCarnival 2026

Promoting "Technology for Good" Through Innovation and Creativity HONG KONG, Oct. 24, 2026 /PRNewswire/ -- The Hong Kong Academy for Gifted Education (HKAGE) has been invited to participate in InnoCarnival 2026, organised by the Innovation and Technology Commission. Under the theme "Tec...
Sat, Oct 24

19th EU-China Business Meeting Concludes! Third-Generation Triple-Helix Biomimetic Collagen Medical Devices Make Their Global Debut, Highlights from the Event

CHENGDU, China, Oct. 24, 2026 /PRNewswire/ -- At the 19th EU-China Business Meeting, co-hosted by the China Chamber of International Commerce (CCOIC) and the European Union Chamber of Commerce in China (EUCCC) in Chengdu, LivingPHOENIX Regenerative Technology Development (Chengdu) Co., Ltd. (hereina...
Sat, Oct 24

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026 /PRNewswire/ -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced...
Sat, Oct 24

Trick or Treat, Collect 'Em All -- CASEKOO Unleashes Limited-Edition Spooky Commemorative Postcards for Halloween

LOS ANGELES, Oct. 24, 2026 /PRNewswire/ -- Toast to 10 years of CASEKOO with the debut of all-new, limited-edition Spooky Season Commemorative Postcards! These eerie, collectible cards pair perfectly with any new iPhone case and are souvenir-worthy and frightfully ready! Since last week, at the bran...
Fri, Oct 23
tradingkey.logotradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.